FDA Delays Hand Roche Extra Year of Drug Patent Protection
Published Date: 12/10/2025
Notice
Summary
Hoffman-La Roche just scored a one-year extra patent life for their drug Bitopertin because the FDA’s approval process is still underway. This means the company keeps exclusive rights to sell Bitopertin oral tablets until December 17, 2026, giving them more time to make money before others can copy it. If the FDA takes longer, they can get up to five one-year extensions, so the clock keeps ticking in their favor!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Up to Five One-Year Extensions Possible
Under 35 U.S.C. 156(d)(5), the term of a patent may be extended for no more than five interim periods of up to one year each if the Food and Drug Administration approval phase is expected to extend beyond the patent's expiration. This means the patent owner may seek up to five separate one-year interim extensions if the FDA approval phase continues to delay beyond expiry.
One-Year Patent Extension Granted
The U.S. Patent and Trademark Office granted a one-year interim extension of U.S. Patent No. 7,319,099 for the drug Bitopertin (GlyT1 inhibitor) oral tablets. The patent's original expiration date of December 17, 2025 is extended by one year to December 17, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14388, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Admission to Practice and Roster of Registered Patent Attorneys and Agents Admitted to Practice Before the United States Patent and Trademark Office
The USPTO is asking for public feedback on its paperwork rules for patent attorneys and agents who want to practice before the office. This helps keep the process smooth and fair without making people fill out too many forms. If you have thoughts, send them in by August 17, 2026—no fees or big changes are happening right now, just a review.
Previous / Next Documents
Previous: 2025-22422, Information Collection: Scheduling Information for the Licensing of Accident Tolerant, Higher Burnup, and Increased Enrichment Fuels
The Nuclear Regulatory Commission is renewing its info collection about scheduling licenses for new, safer nuclear fuels that last longer and use more energy. This affects nuclear companies who need to share their plans with the NRC. Comments on this renewal are open until February 9, 2026, with no new costs expected, just smoother licensing updates.
Next: 2025-22425, Agency Information Collection Activities; Proposed Renewal; Comment Request: Renewal Without Change of Information Collection Requirements in Connection With the Imposition of Special Measures
FinCEN is renewing its paperwork rules tied to special measures against certain risky money laundering groups—without making any changes. Banks and businesses affected by these rules should keep following the same info-sharing steps, and the public can comment until February 9, 2026. This renewal keeps things steady with no new costs or surprises, just a smooth continuation of current requirements.